Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Lawrence F. Eichenfield(University of California San Diego), Marius Ardeleanu(Regeneron (United States)), Thomas Bieber(CK-CARE), Mette Deleuran(Aarhus University Hospital), Bolanle Akinlade(Regeneron (United States)), Regina Fölster‐Holst(University Hospital Schleswig-Holstein), Neil M.H. Graham(UK Dementia Research Institute), Lisa A. Beck(University of Rochester Medicine), George D. Yancopoulos(Regeneron (United States)), Diamant Thaçi(University of Lübeck), Carlos Ferrándiz(Universitat Autònoma de Barcelona), Zhen Chen(Qingdao University), Gianluca Pirozzi(Sanofi (United States)), Jonathan I. Silverberg(George Washington University), Eric L. Simpson(Oregon Health & Science University), Marjolein de Bruin‐Weller(Netherlands Center for Occupational Diseases)
Cited by 181
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k